Product Dossier
Q-VAX
Product Dossier for Q-VAX (Coxiella burnetii, Seqirus). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Seqirus
- Active ingredient: Coxiella burnetii
- Therapeutic area: Infectious Disease
- Same area: RETROVIR
- Same area: Savacol Antiseptic Mouth & Throat Rinse
What it is
Q-VAX is a Q fever vaccine containing inactivated Coxiella burnetii.
Approved indications —
Prevention of Q fever.
Regulatory history
Q-VAX was first registered on the Australian Register of Therapeutic Goods on 23 April 2004. A skin test formulation for pre-vaccination screening was registered on the same date. An updated formulation (25 micrograms per 0.5 millilitre suspension for injection in vial presentation) was registered on 17 April 2026.